|
|
||||||||
release in beryllium-stimulated peripheral blood mononuclear cells
1 Laboratory of Clinical Pathology, and 2 Division of Respiratory Diseases of the University of "Tor Vergata", National Institute for Infectious Diseases (L. Spallanzani, IRCCS), Rome, 3 Division of Occupational Medicine, Policlinico, Modena, and 4 Division of Pulmonary Medicine, Policlinico, Modena, Italy. 5 Pulmonary and Intensive Care Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA
CORRESPONDENCE: M. Amicosante, Laboratory of Clinical Pathology, INMI L. Spallanzani-IRCCS, Via Portuense 292, I-00149, Rome, Italy. Fax: 39 065582237. E-mail: amicosante@inmi.it
Keywords: berylliosis, cytokines, human leukocyte antigen-DPGlu69, interferon-
, T-cell proliferation, tumour necrosis factor-
Received: November 16, 2001
Accepted June 12, 2002
This study was supported by grants from US Dept of Energy (DoE) grant DE-FG02-93ER61714 and grant 99060855594 from MIUR, Italy.
Berylliosis is a granulomatous disorder of the lung caused by inhalation of beryllium (Be) and dominated by the accumulation of CD4+ T-helper (Th)1 memory T-cells proliferating in response to Be in the lower respiratory tract. Two gene markers have been associated with susceptibility to berylliosis: 1) the human leucocyte antigen (HLA)-DP gene whose allelic variants, carrying glutamate in position 69 of the ß-chain (HLA-DPGlu69), can bind Be directly and present it to interferon (IFN)-
In order to determine whether TNF-
While proliferation and IFN-
In conclusion, these data suggest that the tumour necrosis factor-
releasing Th1 T-cell clones from patients with berylliosis; and 2) the cytokine gene tumour necrosis factor (TNF)-
which has been shown to increase berylliosis risk independent of HLA-DPGlu69.
release was triggered by Th1 T-cell activation by Be stimulation in the context of HLA-DPGlu69 molecules, the proliferation of BeSO4-stimulated blood mononuclear cells and the release of IFN-
, TNF-
, RANTES (regulated on activation normal T-cell expressed and secreted), granulocyte-macrophage colony-stimulating factor, interleukin (IL)-4, IL-6, IL-8, IL-10 and IL-12 by BeSO4-stimulated blood mononuclear cells was quantified in 11 individuals with berylliosis using an anti-HLA-DP antibody as a probe for HLA-DP restricted T-cell activation.
release were completely abrogated by HLA-DP inhibition (inhibition with anti-HLA-DP monoclonal antibody (mAb): 88±16 and 77±16%, respectively; anti-HLA-DR: 29±38 and 14±10%, respectively), the release of TNF-
was not (inhibition with anti-HLA-DP mAb: 8.9±7.8%). No other cytokine was detected at significant levels. Moreover, Be was able to induce TNF-
production in healthy control subjects not exposed to Be in the absence of T-cell proliferation and IFN-
production.
response of mononuclear cells is independent of the activation of beryllium-specific human leucocyte anitgen-DP restricted T-cells, which is consistent with the finding that the tumour necrosis factorA2 and the human leucocyte anitgen-DPGlu69 genetic markers are independently interacting in increasing berylliosis risk.
This article has been cited by other articles:
![]() |
R. T. Sawyer, A. P. Fontenot, T. A. Barnes, C. E. Parsons, B. C. Tooker, L. A. Maier, M. M. Gillespie, E. B. Gottschall, L. Silveira, J. Hagman, et al. Beryllium-Induced TNF-{alpha} Production Is Transcription-Dependent in Chronic Beryllium Disease Am. J. Respir. Cell Mol. Biol., February 1, 2007; 36(2): 191 - 200. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Muller-Quernheim, K. I. Gaede, E. Fireman, and G. Zissel Diagnoses of chronic beryllium disease within cohorts of sarcoidosis patients Eur. Respir. J., June 1, 2006; 27(6): 1190 - 1195. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. T. Sawyer, C. E. Parsons, A. P. Fontenot, L. A. Maier, M. M. Gillespie, E. B. Gottschall, L. Silveira, and L. S. Newman Beryllium-Induced Tumor Necrosis Factor-{alpha} Production by CD4+ T Cells Is Mediated by HLA-DP Am. J. Respir. Cell Mol. Biol., July 1, 2004; 31(1): 122 - 130. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. P. Barna, D. A. Culver, B. Yen-Lieberman, R. A. Dweik, and M. J. Thomassen Clinical Application of Beryllium Lymphocyte Proliferation Testing Clin. Vaccine Immunol., November 1, 2003; 10(6): 990 - 994. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |